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Graphical abstract 
 
Highlights 
 One step synthesis of MTX-PGA conjugates was succeeded with high molar MTX 
content. 
 The conjugates with ester linker self-assembled to physically stable nanoparticles. 
 The MTX release were sustained in buffer pH 7.4 but accelerated by esterase enzyme. 
 MTX-PGA NPs had lower potency in 791T but higher toxicity to Saos-2 cells than 
MTX. 
 MTX-PGA NPs showed extremely higher potency in 791T cells than HSA-MTX 
conjugates. 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
3 
 
 
Abstract 
Polymer-drug conjugates have been actively developed as potential anticancer drug delivery 
systems. In this study, we report the first polymer-anticancer drug conjugate with poly(glycerol 
adipate) (PGA) through the successful conjugation of methotrexate (MTX). MTX-PGA 
conjugates were controllably and simply fabricated by carbodiimide-mediated coupling reaction 
with various high molar ratios of MTX. The MTX-PGA conjugate self-assembled into 
nanoparticles with size dependent on the amount of conjugated MTX and the pH of medium. 
Change in particle size was attributed to steric hindrance and bulkiness inside the nanoparticle 
core and dissociation of free functional groups of the drug. The MTX-PGA nanoparticles were 
physically stable in media with pH range of 5-9 and ionic strength of up to 0.15 M NaCl and 
further chemically stable against hydrolysis in pH 7.4 medium over 30 days but enzymatically 
degradable to release unchanged free drug. Although 30%MTX-PGA nanoparticles exhibited 
only slightly less potency than free MTX in 791T cells in contrast to previously reported human 
serum albumin-MTX conjugates which had >300 times lower potency than free MTX. However, 
the MTX nanoparticles showed 10 times higher toxicity to Saos-2 cells than MTX. Together 
with the enzymic degradation experiments, these results suggest that with a suitable 
biodegradable polymer a linker moiety is not a necessary component. These easily synthesised 
PGA drug conjugates lacking a linker moiety could therefore be an effective new pathway for 
development of polymer drug conjugates.  
Keywords: Poly(glycerol adipate); Methotrexate; Polymer-drug conjugate; Nanoparticle; 
Osteosarcoma cell 
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HSA-MTX, Human serum albumin-methotrexate conjugates; MTX, Methotrexate; MTX-PGA, 
Methotrexate-conjugated poly(glycerol adipate); PCE, Porcine carboxylesterase enzyme; PDC, 
Polymer-drug conjugates; PGA, Poly(glycerol adipate) 
1. Introduction 
Polymer-drug conjugates are once more being actively pursued as potential anticancer agents, 
and a range of different drugs and polymers are under investigation [1]. Drugs are required to be 
both potent in molar terms and have a chemical functional group for effective delivery which 
gives a limited choice, and among the favourites from earlier studies was methotrexate (MTX). 
There is also a close connection between polymer drug delivery and targeted drug delivery in 
which drugs are linked to antibodies, and MTX was the first drug to be used for this type of work 
[2].  The fields of polymer-drug conjugates and antibody targeted MTX are also connected 
through work by Garnett and co-workers who constructed human serum albumin-MTX (HSA-
MTX) conjugates linked to monoclonal antibodies which were particularly potent and selective 
[3, 4]. This early work on antibody-MTX conjugates has been comprehensively reviewed [5]. 
MTX still has some advantages in polymer-drug conjugates, as unlike the anthracyclines it is 
quite robust chemically, but has similar potency in sensitive cancers.  
Many efforts have been made to develop macromolecular based drug delivery systems for MTX 
including polymer-drug conjugates, microparticles and nanoparticles [6, 7]. Several polymers 
have been proposed to deliver MTX using a polymer-drug conjugate approach such as human 
serum albumin [8], poloxamer [9], hydroxyethyl starch [10], polypeptide [11], poly(L-lysine) 
[12], chitosan [13, 14]. Polymer-MTX conjugates can circumvent drug resistance, increase 
MTX’s half-life and potentiate its antitumour efficacy better than the MTX-physically-entrapped 
particulate carriers [12, 15]. One of the principal causes of MTX resistance is due to 
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downregulation of uptake pathways, and it has been shown that resistance can be largely 
overcome by macromolecular conjugates delivered by the lysosomotropic route [16]. A key 
feature of polymer-drug conjugates is that a biodegradable linkage is required to release drug at 
the target site through a lysosomotropic mode of action [17, 18]. For many of the earlier 
conjugates with HSA and poly-L-lysine, it appears to be assumed that these amide-linked natural 
and semisynthetic polymers would release drug due to the proteolytic degradation in the 
lysosomal compartment. However, later work by Fitzpatrick and Garnett showed that this 
degradation was limited and inefficient, and led largely to the release of lysyl-MTX derivatives 
[19, 20].  
In addition to the limited number of drugs which can be conjugated, there are also a limited 
number of suitable functional polymers for producing polymer-drug conjugates.  Key work on 
understanding polymer-drug conjugates employed hydroxypropyl methacrylamide, a plasma 
expander [21].  However, as this was a non-biodegradable polymer, suitable linkages to release 
the drug had to be incorporated and many such linkages have been described [1, 22], but these 
are mainly designed for drugs like doxorubicin attached by a free amine on the drug. A suitable 
linkage has also been developed for MTX release [19, 20], however, non-biodegradable 
polymers have a further disadvantage in that they can be difficult to eliminate from the body. For 
the production of the simplest and most effective polymer-drug conjugates, a biodegradable 
functional polymer would be the best way forward, eliminating the need for inclusion of a 
degradable linker.  
Poly(glycerol adipate) (PGA) has been introduced in the pharmaceutical and drug delivery fields 
due to its versatility and well-suited characteristics for potential clinical use. It consists of two 
non-toxic monomers, namely glycerol and adipic acid, linked with ester bonds [23]. Major 
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advantages of PGA are biocompatibility with the body and biodegradability by human enzymes 
producing non-toxic removable metabolites [24]. Further major advantages over other 
biodegradable amphiphilic polymers is that every repeating unit of PGA contains a pendant 
hydroxyl group along the polymer backbone offering the potential for high drug loading using an 
easy synthetic route. The conjugation of MTX at available hydroxyl groups of PGA leads to a 
hydrolysable ester linkage of the conjugates which may release the active parent free drug after 
internalisation in cancer cells. Previously used polymers have significant disadvantages. 
Albumin and poly-L-lysine do not result in significant release of free drug [8, 12]. Poloxamer, 
hydroxyethyl starch and chitosan are not significantly biodegradable and polymers such as 
poloxamer have only terminal groups available for conjugation of drug [9, 10, 13, 14]. These 
properties variously result in low drug loading and lower cytotoxicity compared to the parent 
drug. Furthermore, recent work on MTX-conjugated biodegradable poly(ε-caprolactone)-co-
poly(ethylene glycol) required several steps of synthesis and inclusion of a triazole linker 
between drug and polymer [25, 26]. Therefore, the above characteristics of PGA are 
advantageous and potential for anticancer drug delivery. Up to now, there have been no reports 
on polymer-anticancer drug conjugates using PGA as a backbone.  
The aim of the present work is to synthesise MTX-PGA polymer-drug conjugates and to 
determine their properties. Due to the amphiphilicity of the polymer [27], the polymer-drug 
conjugates are expected to be assembled into small nanoparticles in a similar fashion to that 
reported by the Kataoka group on PEG-polyaspartate-adriamycin conjugate micelles [28]. Also 
we aim to assess their efficacy for this work in comparison to historical efficacy data on HSA-
MTX conjugates to help elucidate mechanistic advantages which may lead to development of 
more effective polymer-drug conjugates for cancer therapy. 
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2. Materials and methods 
2.1. Materials 
PGA was synthesized according to the previously published method [29]. MTX and porcine 
carboxylesterase (PCE, with activity of 18 units/mg solid) were used as received from Sigma-
Aldrich, Missouri, USA. N,N'-Dicyclohexylcarbodiimide (DCC), 4-(dimethylamino)pyridine 
(DMAP) were bought from Fluka, Tokyo, Japan.  Osteosarcoma cell line 791T originally 
obtained from the U.S. Naval Biomedical Center, Oakland, USA [30], was obtained from Prof L 
Durrant, Department of Medicine, Nottingham City Hospital, University of Nottingham, a 
culture of the cell line used in the works originally published by Garnett et al [3, 4, 19, 20]. Saos-
2 cell line (human primary osteogenic sarcoma, ATCC number HTB-85) was kindly gifted from 
Dr. Pakpoom Kheolamai, Division of Cell Biology, Faculty of Medicine, Thammasat University, 
Thailand. Eagles Minimum Essential Medium (MEM) and glutamine solution were obtained 
from Sigma-Aldrich (Dorset, UK). Dulbecco’s modified Eagle’s medium (DMEM) powder, low 
glucose, Dulbecco’s phosphate buffered saline (DPBS) without calcium chloride without 
magnesium chloride and PrestoBlue® cell viability reagent were purchased from Life 
Technologies Corporation, Oregon, USA. Sodium pyruvate was obtained from Merck KGaA, 
Damstadt, Germany. 0.05% Trypsin-EDTA was collected from Gibco® (Invitrogen Ltd, Paisley, 
UK). Resazurin was sourced from Acros Organics (Loughborough, UK). Foetal bovine serum 
(FBS) was supplied by Invitrogen Ltd (Paisley, UK). Commercially available sterile 
methotrexate solution for injection (25 mg/mL) was obtained from Mylan, Hatfield, UK. 
Dimethyl formamide (DMF) and acetonitrile were of high performance liquid chromatography 
(HPLC) grade and used as received. Dimethyl sulfoxide (DMSO) was dried using molecular 
sieves prior to use. Water employed throughout this study was deionized (DI) grade or higher.  
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2.2. Synthesis of MTX-conjugated PGA (MTX-PGA) polymers 
Conjugates of varying nominal MTX % mole with respect to PGA polymer repeating unit were 
produced by a simple carbodiimide coupling reaction. In brief, PGA (1 g = 4.95 mmole glycerol 
adipate repeating units) was dissolved in dried DMSO (10 mL). Calculated amounts of MTX 
(1.5 equiv.), DCC (1.2 equiv.) and DMAP (0.3 equiv.) relative to the mol% nominal value of 
polymer repeating units were then added. The reaction was stirred for 72 h and protected from 
light. After that, the precipitate was removed by centrifugation at 4500 rpm, 4°C for 15 min. The 
supernatant was collected and precipitated in methanol. The precipitate was washed with 
methanol for another 3 times and re-dissolved in a small volume of DMSO. The polymer 
solution was dialyzed against DI water for 24 h using dialysis bag (MWCO 12,400 Da, Sigma-
Aldrich, Missouri, USA). Finally, the polymer was freeze dried for 24 h. The dried polymer was 
kept in a desiccator until use.  
2.3. Polymer characterization 
2.3.1. IR spectroscopy 
Presence of drug in conjugated PGA polymer was first assessed by infrared (IR) spectroscopy 
using an Attenuated Total Reflection (ATR) spectrometer (Agilent Cary 630 FTIR, Agilent 
Technologies, Santa Clara, USA). The spectra were recorded with a resolution of 4 cm-1 over the 
range of 4000-650 cm-1 by recording 32 interferograms. 
2.3.2. Nuclear magnetic resonance (NMR) spectroscopy 
The quantitation of drug coupling and structure of MTX-PGA polymers were investigated by 
proton 1H NMR spectroscopy. The spectra were recorded by Bruker 400 MHz spectrometer 
(Bruker corporation, Rheinstetten, Germany) using DMSO-d6 as a solvent.  
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MTX-PGA (DMSO-d6; δ, ppm): 8.58 (s, 1H), 7.72-7.74 (m, 2H), 6.82-6.84 (d, 2H), 5.26-5.19 
(m, 2H), 4.95 (m, 1H), 4.79 (s, 2H), 4.37 (t, 1H), 4.23 (m, 2H), 4.18-3.88 (m, 6H), 3.63 (m, 2H), 
3.21 (s, 3H), 2.32 (m, 4H), 2.09 (m, 2H), 1.96 (m, 2H), 1.53 (m, 4H). 
PGA (DMSO-d6; δ, ppm): 5.26-5.19 (m, 2H), 4.95 (m, 1H), 4.27-4.24 (m, 2H), 4.18-3.88 (m, 
6H), 3.63 (m, 2H), 2.32 (m, 4H), 1.53 (m, 4H). 
2.3.3. Gel permeation chromatography (GPC) 
The molecular weights (number- and weight-average, Mn and Mw, respectively) were measured 
by gel permeation chromatography (PL50 Plus Polymer Laboratories system) equipped with a 
refractive index detector. Two mixed PL-Gel 5 µm bed (D) columns maintained at 50°C were 
used as a stationary phase using DMF containing 0.1% LiBr at a ﬂow rate of 1 mL/min as an 
eluent. Poly (methyl methacrylate) standards (Mn range of 1,810,000-505 g/mol) were employed 
to construct a calibration curve.  
2.3.4. UV analysis of MTX content 
The amount of conjugated MTX was analysed by UV/Vis spectrophotometer (UV-2600, 
Shimadzu Corporation, Kyoto, Japan). The absorbance value of the polymers was measured in 
DMF at a wavelength of 412 nm. The amount of conjugated MTX was calculated from a 
calibration curve of MTX over the range of 5-100 μg/mL. The molar absorptivity of MTX in 
DMF was 3.6643×103 M-1. 
2.4. Nanoparticle formation 
The nanoparticles of MTX-PGA polymers (MTX-PGA NPs) were prepared by a solvent 
diffusion and dialysis method [26]. In brief, 10 mg of the polymer was dissolved in 1 mL of 
DMSO. This solution was then added dropwise to 1 mL of aqueous phase while stirring to allow 
solvent diffusion. Then the colloidal dispersion was sealed in a dialysis tube (MWCO 1 kDa, 
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Spectra/Por® 6, Spectrum Laboratories, Inc., Dominguez, USA) for 24 h. The assembled 
nanoparticles were collected and kept as a dispersion until use.  
2.5. Analyses of particle size, size distribution and zeta potential 
The mean hydrodynamic diameter (z-ave), size distribution (PDI) and zeta potential (ZP) were 
assessed by Zetasizer NanoZS (Malvern Instrument Ltd., Malvern, UK). The sample without 
dilution was measured with He-Ne laser at a wavelength of 633 nm, an angle of 173° and 25°C. 
The ZP of nanoparticles was evaluated according to the electrophoretic mobility of the particles 
and calculated by the Helmholtz-Smoluchowsky equation. All measurements were performed in 
triplicate. 
2.6. Physical stability of nanoparticles in various pHs and ionic strengths 
To evaluate effects of pH and ionic strength of medium on the stability of the nanoparticles, the 
nanoparticles were diluted 10-fold in water adjusted to various pHs (1-13) using 5 M HCl or 
NaOH and to different ionic strengths (0.05-0.50 M sodium chloride solution; NaCl) using 5 M 
NaCl solution, respectively [31]. After mixing for 5 min, the sample was examined for 
hydrodynamic diameter, PDI and derived count rate. The derived count rate reflecting 
aggregation, sedimentation or dissociation of the nanoparticles is illustrated as kilo counts per 
second (kcps). The results are expressed as relative values of hydrodynamic diameter, PDI or 
kcps in the changed medium compared to an equal dilution of the nanoparticles in sterile water 
for injection. 
2.7. In vitro non-enzymatic and enzymatic drug release studies 
The drug release study of MTX-PGA NPs was performed in 25 mM phosphate buffered saline 
(PBS) pH 7.4 by dialysis method [26]. A typical protocol for release study was as follows. 
Freshly prepared MTX-PGA NPs (1 mL) were measured into a dialysis bag (MWCO 1000 Da, 
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Spectra/Por 6, Spectrum Laboratories, Inc., Dominguez, USA). The tightly sealed bag was 
immersed in the external medium (20 mL PBS pH 7.4 containing 0.02% w/v sodium azide). The 
release study was conducted at 37°C in the light-protected container with magnetic stirring at 
100 rpm. At predetermined times, sample (1 mL) was withdrawn from the external medium and 
was replenished with an equal volume of fresh PBS. In the case of enzymatic drug release study, 
porcine carboxylesterase (PCE) enzyme was mixed with the nanoparticle dispersion yielding 20 
and 50 units/mL of PCE [32-34]. The NPs mixture was filled into the dialysis bag and the release 
study was similarly performed as previously described. The enzymatic release study was 
conducted for 7 days. The MTX solution was employed as a control. The amount of MTX in the 
sample was analysed by HPLC (Shimadzu HPLC apparatus, Shimadzu Corporation, Kyoto, 
Japan) using Luna C18 column 150×4.6 mm plus a C18 guard column (Phenomenex, Torrance, 
USA) as a stationary phase and the mixture of 10% v/v acetonitrile and 90% v/v 0.05 M 
phosphate buffer pH 6.0 at a flow rate of 1.2 mL/min as a mobile phase.  
2.8. Cytotoxicity test in 791T osteosarcoma cells 
2.8.1. Cell culture experiment 
The osteosarcoma cell line 791T was grown as a monolayer in tissue culture polystyrene flasks 
in Eagles Minimum Essential Medium with the addition of 10% foetal bovine serum and 20 mM 
glutamine. Medium was changed every 2-3 days and cells were detached using 0.05% trypsin-
EDTA for subculture. The cells were kept in an incubator at 37°C with a humidified atmosphere 
with 5% CO2. 
2.8.2. Drug solution and nanoparticle suspension preparation 
Commercially available sterile MTX solution for injection (25 mg/mL, 55 mM in saline), and 
sterile-filtered nanoparticle suspensions (115-173 µM MTX equivalent) in PBS were diluted in 
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cell-culture medium to 9 half-log10-spaced concentrations spanning from (2 nM to 200 µM). 
MTX concentrations for the nanoparticle suspensions were calculated from UV absorption 
measurements. Drugs and nanoparticles were added as 2× solutions (100 µL/well) to build a 
dose-response from 1 nM to 100 µM. PBS concentration in all wells was kept at 10% v/v. For 
incubations longer than 72 h, media was refreshed with solutions/suspensions with the nominal 
MTX concentration equivalent. There were 6 technical replicates for each condition. 
2.8.3. Drug treatment in monolayer 
791T cells were seeded in flat bottom cell culture treated 96-well plates (100 µL, 
20×103 cells/mL) and left in the incubator for 24 h. Drug solution and nanoparticle suspensions 
were added from 2× stocks and left for 72 h. For the 6-day treatment experiments in monolayer, 
the old medium (150 µL) was removed, replaced with fresh drug solution (150 µL) and the cells 
cultured for another 72 h. On days 4 and 7 cell viability was determined using the resazurin 
assay. 
2.8.4. Drug treatment for spheroid cultures 
791T cells were seeded in round bottom ultra-low attachment 96-well plates (100 µL, 10×103 
cells/mL) and left to incubate for 72 h. MTX and MTX-PGA NPs were added on day 3 from 2× 
stock solutions, then refreshed on day 6. Spheroids were imaged on days 3, 6, and 9 and 
resazurin activity was determined on days 6 and 9. 
2.8.5. Resazurin assay 
Assay-ready resazurin solution (60 µM) was prepared from resazurin stock solution (440 µM in 
Hank’s Buffered Salt Solution) and fresh cell culture media. Spent medium (150 µL) was 
removed from each well and replaced with the same volume of assay resazurin solution. Cells in 
monolayer were incubated for 2 h, while spheroids were left for 4 h in the incubator. 
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Fluorescence was measured with an excitation wavelength of 530 nm and emission 590 nm on a 
Flexstation II plate reader. 
2.8.6. Spheroid imaging 
Brightfield spheroid images were acquired with a Nikon Ti Eclipse inverted microscope using 4 
× objective. Spheroid volume was determined with an in-house open source macro for the FiJi 
distribution of ImageJ [35, 36]. 
2.9. Cytotoxicity test in Saos-2 osteosarcoma cells 
2.9.1. Cell culture experiment 
Saos-2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% FBS and penicillin/streptomycin (100 units/mL) in a 5% CO2 humidified incubator at 37°C. 
The medium was change every 2-3 days. For subculture, the cells were trypsinised using 0.25% 
trypsin-EDTA. 
2.9.2. Drug solution and nanoparticle suspension preparation 
MTX stock solution was prepared in Dulbecco’s PBS pH 7.4. The stock solutions of MTX and 
nanoparticles were filtered through sterile 0.22 µm syringe filter and subsequently diluted in 
DMEM to the concentration range of 0.002 – 220 µM.  
2.9.3. Drug treatment in Saos-2 monolayer 
Saos-2 cells (100 µL) were seeded in 96-well plate at a cell density of 2,000 cells/well and 
incubated under 5% CO2 humidified atmosphere at 37°C for 24 h. After aspirating the medium, 
100 µL of sample was subsequently added into each well and the cells were incubated for 72 h. 
After that PrestoBlue® cell viability reagent (10 µL) was added in each well and then incubated 
for 50 min in the incubator. The absorbance was measured at 570 and 600 nm as measuring and 
reference wavelengths, respectively, by a microplate reader (Tecan’s Infinite® 200 NanoQuant, 
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Männedorf, Switzerland). The measurement was performed in six replicates for at least 2 
different days.  
2.10. Statistical analysis 
The z-ave, PDI and ZP of MTX-PGA NPs were statistically compared using one-way ANOVA 
(IBM SPSS statistic 21). The significant difference is considered when p-value is less than 0.05.  
Data from resazurin experiments were normalized to untreated controls (100% viability) and 
cell-free wells (0% viability). The volume of untreated spheroids was taken as 100% viability 
and 0 as 0% viability. Four-parameter logistic dose-response curves were fitted to the resazurin, 
volume and  PrestoBlue® data in GraphPad Prism, the top was constrained to 100 and the bottom 
to ≥0. IC50s used are the inflection point of the dose-response curve, half-way between the 
untreated controls (100%) and the curve bottom (maximum effect). Results are displayed as 
mean ± SD unless stated otherwise. 
3. Results and Discussion 
3.1. Conjugation of MTX onto PGA backbone 
By a simple coupling reaction, various amounts of MTX were successfully conjugated to the 
PGA backbone, which were designated X%MTX-PGA, with X corresponding to the nominal 
mole% MTX per polymer repeating unit. As compared to the IR-ATR spectrum of PGA (Fig. 
1A), the sharp C=O stretching peak at 1718 cm-1 corresponding to the ester coupling of MTX 
and glycerol adipate repeating unit overlapped to that ester along the PGA backbone. Other 
characteristics of MTX were also observed in the spectra. The peaks of N-H bending of amine, 
C=O stretching of amide bond, C=C stretching of aromatic ring of MTX were overlapping to 
each other at 1624, 1600 and 1553 cm-1, respectively. However, the intensity of these peaks 
increased with the MTX content. The peaks of N-H stretching of amine and amide occurred over 
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the region of 2950-2800 cm-1 which overlapped with O-H stretching of PGA. As previously 
reported on the NMR spectrum of PGA, the adipic protons presented at 1.5 and 2.3 ppm in 
DMSO-d6 (Fig. 1B) which slightly shifted to upfield region as compared to those in acetone-d6 
[29]. Meanwhile, the protons related to glycerol repeating units were apparent in the region of 
3.6 ppm and 4.9 ppm. The methine protons corresponding to 1,2 and 1,3 di-substituted 
glycerides occurred at 5.20 ppm coinciding with the presence of the methine proton of 1,2,3 tri-
substituted glycerol units at 5.26 ppm. The latter proton indicates the tri-substituted repetitive 
glycerol unit of PGA polymer. The conjugation of MTX at free hydroxyl group available on 
glycerol units resulted in the shift of methylene proton peaks from 3.6 ppm to 4.2 ppm. The 
methine proton at 5.26 ppm increased when higher amounts of MTX were conjugated, 
confirming the functionalization of the secondary hydroxyl group. The glycerol and adipic 
protons of MTX-PGA polymers were still observed at a similar chemical shift to those of PGA. 
In addition, the characteristic protons of MTX were also observed in the NMR spectra.  
Fig. 1 
The percent MTX conjugation can be calculated from NMR spectra based on the pteridine 
proton of MTX at 8.58 ppm and the methylene protons in adipate units of PGA at 2.32 ppm as 
shown in the equation (1). The methine proton at 5.26 ppm could not be accounted for in the 
calculation of %conjugated MTX due to the interference of methine proton of di-substituted 
repeating units. The results are illustrated in Table 1. The % conjugated MTX was found to be 
7.0, 14.5 and 27.5% with respect to number of repeating units of PGA chain for 10%, 20% and 
30%MTX-PGA, respectively. Using these NMR data, the conjugation efficiency based on 
theoretical conjugation reached 58.3, 60.4 and 76.4% for 10%, 20% and 30%MTX-PGA, 
respectively. The amount of conjugated MTX was further confirmed by UV spectrophotometry. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
16 
The analysed amount of MTX was found to be 8.86±0.32, 17.33±1.25, 33.26±4.72 %mole MTX 
conjugated per mole of polymer repeating unit. The difference between the analysis using NMR 
and UV spectrophotometry is probably due to changes in extinction coefficients on conjugation 
of MTX. 
𝐼8.58 𝑝𝑝𝑚 1⁄
𝐼2.32 𝑝𝑝𝑚 4⁄
× 100         (1) 
where I8.58 ppm and I2.32 ppm are the integrals of pteridine proton of MTX at 8.58 ppm and 
methylene protons in adipate repeating units of PGA at 2.32 ppm, respectively. 
Table 1 
The Mn of PGA starting materials was 13000 g/mol. After conjugation, the Mn of MTX-PGA 
polymers increased gradually with %MTX conjugation. The Mw/Mn values of all MTX-PGA 
polymers decreased compared to that of PGA due to the purification of polymer by precipitation 
in which the unconjugated PGA could be removed during washing which may tend to selectively 
remove the lower molecular weight polymers. These results indicated that MTX was 
successfully conjugated along PGA backbone by a simple carbodiimide-mediated coupling 
reaction.  
3.2. Nanoparticle formation 
The MTX-PGA NPs were prepared in deionized water by solvent diffusion-dialysis method. As 
shown in Fig. 2, the hydrodynamic diameter of MTX-PGA NPs tended to increase with %MTX 
except for 20%MTX-PGA nanoparticles whose value was extraordinarily larger than the others. 
The particle size of 20% and 30%MTX-PGA was approximately 6 and 2 times larger than 
10%MTX-PGA NPs, respectively. The increasing particle size with drug loading may be due to 
higher steric hindrance and bulkiness inside the nanoparticle core as a result of poor packing of 
drug moiety as seen in the case of 20%MTX-PGA NPs. Meanwhile, for 30%MTX, a better 
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compaction of the nanoparticles was achieved, probably due to increased hydrophobicity of the 
polymer-drug conjugates. The size distribution of 10% and 30%MTX-PGA NPs was narrow 
while, that of 20%MTX-PGA NPs was quite broad. The size distribution related to the diameter 
of the nanoparticles. A greater negative surface charge of nanoparticles was observed when 
increasing %MTX in particular to 30%MTX-PGA NPs indicating that an increasing number of 
MTX moieties was displayed on the nanoparticle surface. Combining the results of 
hydrodynamic diameter and zeta potential, the dramatic size increase of 20%MTX-PGA NPs 
was thought to result from destabilization of the nanoparticles followed by agglomeration upon 
particle formation. 
Fig. 2 
From these results, we anticipated that the pH of preparation medium may affect the particle 
formation due to a presence of pH-sensitive moiety in the drug molecule. Therefore, the effect of 
pH of preparation medium was further investigated. Two pH media were used, namely acidic pH 
3.0 medium and pH 7.4 medium. As expected, the pH of preparation medium considerably 
affected the hydrodynamic diameter. In medium pH 7.4, the particle size decreased with 
increasing %MTX. Meanwhile, the diameter of nanoparticles gradually increased in acidic pH 
3.0 medium with increasing %MTX. This result was likely caused by the acid dissociation of 
MTX in different medium pHs. MTX possesses three pKa value ranges of 3.3-3.4, 3.9-4.7 and 
5.3-5.7 at alpha and gamma carboxyl groups and pteridine ring, respectively [37, 38]. The 
gamma carboxyl of MTX is more reactive so tend to conjugate to hydroxyl pendant of PGA 
more readily resulting in a higher preponderance of free alpha carboxyl group [39], so the free 
carboxyl and pteridine of MTX are involved in the dissociation of MTX in the medium. MTX 
protons were almost totally dissociated in medium pH 7.4 [40] while acid groups remained 
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unionized at pH 3.0. The ionized MTX molecule exhibited more hydrophilicity and favoured an 
aqueous phase. Thus the drug molecules were preferably presented on the surface of particles 
and fewer molecules incorporated in the core thus dramatically reducing the particle size to less 
than 100 nm. On the other hand, the acidic aqueous phase suppressed the dissociation of 
carboxylic group of MTX which enhanced the hydrophobicity of drug molecules and 
nanoparticle core. Thus, it enlarged the MTX-PGA NPs with increasing MTX content. The size 
distribution of the nanoparticles increased in acidic medium but declined in pH 7.4 medium 
relative to that in deionized water. The zeta potential of MTX-PGA NPs became positive and 
more negative in media pH 3.0 and 7.4, respectively. The difference in amount of MTX did not 
affect the zeta potential (p-value>0.05). The change of surface charge of MTX-PGA NPs was 
possibly as a result of ionised hydronium and hydroxyl species in the acidic and pH 7.4 media, 
respectively. 
3.3. Physical stability of nanoparticles in various pHs and ionic strengths 
The physical stability of MTX-PGA NP dispersion was evaluated in various pHs and ionic 
strengths. The relative hydrodynamic diameter, PDI and kcps compared to the nanoparticles 
equally diluted in sterile water for injection are summarised in Fig. 3. Regarding the effect of pH, 
the hydrodynamic diameter of all MTX-PGA NPs increased by at least twice in extremely low 
and high pHs (1-3 and 11-13). The size distribution was also broadened particularly to 
10%MTX-PGA NPs over pH range of 1-3 and 11-13. The relative kcps of MTX-PGA NPs in pH 
1-3 considerably increased especially 20%MTX-PGA NPs whilst it decreased in pH 11-13. 
Principally, an increase of count rate suggests an occurrence of aggregation of particles whereas 
a decrease of count rate indicates the sedimentation or dissociation of nanoparticles [41, 42]. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
19 
Combining the hydrodynamic diameter and kcps data, the MTX-PGA NPs aggregated into large 
particles in media with pH of less than 5 and dissociated or settled down in media pH over 7.  
Fig. 3 
Regarding the effect of ionic strength, the nanoparticles started to aggregate in 0.25 M NaCl as 
seen by dramatic increases of hydrodynamic diameter and PDI. Meanwhile, the increment of 
kcps was initially observed in 0.15 M NaCl particular to 20%MTX-PGA NPs whereas the others 
remained almost unchanged. The results indicated that all MTX-PGA NPs aggregated in the 
medium with NaCl concentration of 0.25 M or higher. 10%MTX-PGA NPs and 30%MTX-PGA 
NPs were physically stable in the medium with 0.15 M NaCl or lower. From the results above, it 
was suggested that the MTX-PGA NPs were physically stable in physiological relevant medium 
with pH range of 5-9 and ionic strength of lower than 0.15 M NaCl.  
3.4. In vitro drug release experiment 
We have chosen carboxylesterase (PCE) as an example of an enzyme which can degrade PGA to 
investigate drug release. The hydrolytic release of MTX from MTX-PGA NPs was investigated 
in PBS pH 7.4 over 30 days. The results are graphically demonstrated in Fig. 4. The control 
MTX solution showed a rapid diffusion from the dialysis tubing with over 90% release within 8 
h. Meanwhile, the MTX release from all MTX-PGA NPs was considerably slower over 30 days 
showing effective conjugation of the drug to the polymer with only a slow hydrolytic 
degradation. The maximum MTX release provided by 30%MTX-PGA NPs reached only 17% at 
day 30. Regarding various %MTX conjugations, the extent of MTX release depended on the 
amount of conjugated MTX. 10%MTX-PGA NPs released the lowest amount of MTX by only 
9% at the end of experiment even though they had smallest average diameter after preparation. 
The presence of esterase enzyme in PBS accelerated the release of MTX from 30%MTX-PGA 
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NPs. Moreover, the rate of MTX release escalated with the PCE concentration. At day 7, 40% 
and 62% of MTX were released in PBS containing 20 and 50 units/mL PCE, respectively. The 
liberated MTX peak in HPLC chromatogram was identical to the MTX standard peak (data not 
shown) suggesting that the degradation of MTX-PGA NPs could be catalysed by esterase 
enzyme liberating intact MTX molecules whose pharmacological activity should not be changed. 
There are a wide range of proteolytic enzymes present in the lysosomal environment with 
different specificities and this can be illustrated with a previous paper by our group which 
reported the uptake and metabolism of PGA nanoparticles in DAOY cells [43]. The PGA 
nanoparticles are taken up by the cells which then enter endosomes and lysosomes and undergo 
fast degradation in the cells.  This environment is likely to result in a much faster and complete 
degradation and drug release than seen in the present experiment. However the above experiment 
demonstrates the potential for an enzymic release of free drug from this polymer which is more 
effective than the release of MTX previously reported from HSA-MTX conjugates using 
lysosomal enzyme preparations [19, 20]. 
Fig. 4 
3.5. Cell response experiment 
To further confirm the potency of MTX-PGA NPs, a cell response experiment was performed in 
osteosarcoma 791T cells. 10%MTX-PGA NPs and 30%MTX-PGA NPs were selected to study 
their cell response in comparison with the clinically available MTX solution. MTX and MTX-
PGA NPs elicited a dose dependent decrease in 791T cell viability after incubation for 72 h (Fig. 
5). The cytotoxic effects of MTX and the nanoparticles were more pronounced in monolayer 
cultures (Fig. 5A), where MTX had an IC50 of 15 nM and killed 75% of cells. These results are 
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in agreement with previous studies on the cytotoxic effects of MTX in monolayer by Garnett et 
al [4]. 
Fig. 5 
Present results of MTX-PGA NPs and historic results with HSA-MTX by Garnett et al. (Fig. S1 
in supplementary data) are compared using 791T cells in 2D cell culture. Values in parenthesis 
give % drug loading w/w as drug loading appears to affect cytotoxicity. The MTX-PGA 
analogues were 2.6 and 11.3 times less potent compared to free MTX. This is significantly better 
compared to the >300× potency differences seen with the HSA-MTX conjugates (Table 2). The 
increased potency of the MTX-PGA analogues compared to HSA-MTX is probably due to the 
quick degradation of PGA in the lysosomes once internalized in the cells. MTX-PGA NPs were 
probably degraded to free drug by enzyme-catalysed hydrolysis as seen in the enzymatic release 
experiment. This is in contrast to HSA-MTX conjugates which mainly released the lysyl-MTX 
derivatives [19, 20]. It has been reported that the efficiency of dihydrofolate reductase inhibition 
of MTX is lowered by conjugation due to steric interference between the enzyme and the 
modified drug [44, 45]. Therefore, the higher potency of MTX-PGA NPs as compared to HSA-
MTX may be attributed to improved free drug release. 
Table 2 
It has been demonstrated in previous publications by our group that there is a greater uptake of 
PGA nanoparticles into DAOY tumour spheroids than for similar mixed rat neonatal normal 
brain cells [46], and we have recently published a convenient method for determination of 
cytotoxicity in spheroid cultures [35]. We have therefore also investigated the cytotoxicity of 
MTX-PGA NPs in 791T spheroids compared to free drug. The results for resazurin reduction in 
791T spheroids were considerably more variable compared to monolayers resulting in 
AC
CE
PT
ED
 M
AN
US
CR
IPT
22 
ambiguous curve-fits (Fig. 5B). Nevertheless, a similar trend was observed, where free MTX 
was the most potent, closely followed by 30%MTX-PGA (1.2 times IC50 difference) and 
10%MTX-PGA was the least potent (30 times IC50 difference). When spheroid volume was used 
to estimate spheroid viability, variability was much lower, curve fitting and the estimation of 
IC50s and maximal effects improved (Fig. 5C). Although MTX was still active in the nanomolar 
range (IC50=45 nM), cell viability remained above 50% even at micromolar concentrations. 
Increased resistance to chemotherapy when cells are cultured in 3D has been reported before [35, 
47, 48]. Notwithstanding the decrease in sensitivity, the potency differences between MTX and 
the MTX-PGA conjugates remained unchanged (Fig. 5D).  Longer incubation periods (6 days) 
produced even more potent responses to MTX with lower IC50s and smaller surviving fraction of 
cells, along with similar potency ratio between the free drug and the conjugates (Fig. S2 in 
supplementary data).  It was disappointing that the 3D culture conditions did not show an 
improvement in relative activity of MTX-PGA/MTX compared to 2D culture but this may be 
due to other factors like the physicochemical properties of the nanoparticles and their cellular 
interactions. 
Further investigation was performed in another osteosarcoma cell line, Saos-2, to further confirm 
whether the MTX-PGA NPs would affect in a similar or different fashion as observed in 791T 
cells. The IC50 values of MTX-PGA NPs against Saos-2 cells are summarised in Table 2. MTX 
had an IC50 of 210.9 µM in Saos-2 and only resulted in 47.7% cell viability even at the highest 
concentration of MTX tested in this study. This value was high in the micromolar range and 
extremely high compared to the value in 791T cells but was consistent with previous studies on 
low MTX-responsive or MTX-resistant Saos-2 cells [49, 50]. In the case of MTX-PGA NPs, 
10%MTX-PGA NPs and 30%MTX-PGA NPs were relatively unresponsive on Saos-2 in 
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comparison to 791T cells with IC50s of 26.8 and 20.2 µM, respectively. Although the IC50 values 
of the nanoparticles on Saos-2 cells were still in the micromolar range, they possessed 7.9 and 
10.4 times higher potency than free drug, respectively. This result revealed that the MTX-PGA 
NPs provided better relative potency in Saos-2 cells than 791T cells suggesting the improved 
efficacy of MTX-PGA conjugates in Saos-2 cells. As evidenced by the previous reports [49, 50], 
the low MTX-responsive or MTX-resistant Saos-2 cells are attributed to a reduction of MTX 
uptake by RFC, an overexpression of DHFR protein, an increment of MTX efflux due to 
overexpression of multidrug resistant protein, a reduction of MTX polyglutamylation, a decrease 
of DHFR affinity to MTX and the combination of these mechanisms [50-52]. The improved 
efficacy in Saos-2 cells by the MTX-PGA NPs may be attributed to overcoming one of the 
resistance mechanisms. Further work will be needed to investigate the mechanistic resistance of 
Saos-2 to MTX and to evaluate whether the MTX-PGA NPs can be used in MTX-resistant 
osteosarcoma. 
5. Conclusion 
Our study showed the feasibility of the conjugation of anticancer drug, MTX, to a PGA 
backbone, the first polymer-anticancer drug conjugate reported with this polymer. The MTX-
PGA conjugates contained high molar MTX content by 27.5 mole% and showed promising 
characteristics in terms of particle properties, physical stability in the physiological medium, 
stability of polymer-drug conjugate linker over 30 days and enzymatic degradability. Although 
the MTX-PGA NPs showed lower cytotoxicity to 791T cells than free MTX, 30%MTX-PGA 
NPs were only slightly less potent than MTX in either 2D or 3D cultures. Nonetheless, the 
nanoparticles exhibited relatively higher toxicity to Saos-2 cells than the parent drug. The 
improved efficacy of MTX in Saos-2 cells rather than 791T cells was possibly due to 
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surmounting MTX-resistant mechanism in this cell. However, further work is needed to 
determine the mechanism overcoming the drug resistance by MTX-PGA NPs. Taking the 
enzymic degradation results together with the cytotoxicity data and previous reports on the 
degradation of PGA in the lysosomal compartment of cells, this strongly suggests that this PGA 
polymer conjugate does not require a complex linker between drug and polymer. This opens the 
way to a possible new paradigm for polymer-drug conjugates which have a simpler synthesis 
together with a more effective mechanism of action. Nevertheless, further improvement of 
potency and greater specificity of the conjugate may be needed for this type of polymer-drug 
conjugate and we are continuing to investigate these possible improvements.   
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Figure 1. IR-ATR spectra (A) and 1H NMR spectra (B) of PGA, MTX and MTX-PGA 
conjugates. 
Figure 2. Mean hydrodynamic diameter (z-ave, A), size distribution (PDI, B) and zeta potential 
(ZP, C) of MTX-PGA NPs at various %MTX conjugations. An error bar indicates the standard 
deviation from three measurements. *Statistically significant difference comparing different 
amount of conjugated MTX (p-value<0.05). **Statistically significant difference compared to 
MTX-PGA NPs prepared in DI water at an equal amount of conjugated MTX (p-value<0.05). 
Figure 3. Relative hydrodynamic diameter (A and D), PDI (B and E) and kcps (C and F) of 
MTX-PGA NPs in various pHs (left column) and ionic strengths (right column) of media as 
compared to those in an equal dilution in sterile water for injection. Error bar indicates standard 
deviation of three measurements. *Statistically significant difference when comparing the same 
formulation in different media (p-value<0.05). **Insignificant difference when comparing the 
same formulation in different media (p-value>0.05). 
Figure 4. Release profiles of MTX from MTX-PGA NPs in PBS pH 7.4 with an absence of 
enzyme for 30 days and the presence of 20 and 50 units/mL PCE at 37°C for 7 days. Error bars 
indicate standard deviation from three experiments.  
Figure 5. Viability of 791T monolayers and spheroids treated with MTX and MTX-PGA NPs 
for 3 days. A-resazurin viability assay for 791T cells treated in monolayer, B-resazurin viability 
assay for 791T spheroids, C-dose-response curves for spheroid volume. D-table summarising the 
IC50 and maximum effect with the corresponding 95% confidence intervals for the estimates. 
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Table 1 Molecular characteristics of PGA and MTX-PGA polymers 
Table 2 Comparison of relative efficacy of polymer-drug conjugates (PDC) with MTX 
 
 
Table 1 Molecular characteristics of PGA and MTX-PGA polymers 
Polymer Mn,GPC Mw/Mn %mole MTX/mole of polymer 
repeating unit 
Conjugation 
efficiency by NMRb 
NMR UV 
PGA 13000 2.70 NDa NDa NDa 
10%MTX-PGA 14621 2.21 7.0 8.86±0.32 58.3% 
20%MTX-PGA 16215 1.61 14.5 17.33±1.25 60.4% 
30%MTX-PGA 18579 1.95 27.5 33.26±4.72 76.4% 
aNot determined 
b𝐶𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =
%𝑀𝑇𝑋𝑁𝑀𝑅
%𝑀𝑇𝑋𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙
× 100; where %𝑀𝑇𝑋𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 =
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑃𝐺𝐴
𝑀𝑊𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙 𝑎𝑑𝑖𝑝𝑎𝑡𝑒
× %𝑀𝑇𝑋𝑇𝑎𝑟𝑔𝑒𝑡 × 1.2 𝑒𝑞𝑢𝑖𝑣. 𝑜𝑓 𝐷𝐶𝐶; %MTXNMR is the %mole MTX 
calculated by NMR per mole of polymer repeating unit, %MTXTheoretical is the theoretical %mole 
MTX per mole of PGA repeating unit, and %MTXTarget is the target %mole of MTX per mole of 
PGA repeating unit and equals to 10, 20, and 30 for 10%, 20%, and 30%MTX-PGA, 
respectively. 
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Table 2 Comparison of relative efficacy of polymer-drug conjugates (PDC) with MTX 
 PDC/MTX 791T cells Saos-2 cells 
IC50 IC50 ratio of 
PDC/MTX 
IC50 IC50 ratio of 
PDC/MTX 
HSA-MTX experiment       
MTXa 29 nM  - - - 
HSA-MTX (16%)a 10,900 nM 377 - - 
MTX-PGA experiment       
MTX 15 nM  - 210.9 µM  
10%MTX-PGA 170 nM 11.3 26.8 µM 0.127 
30%MTX-PGA 39 nM 2.6 20.2 µM 0.096 
aData extracted from Garnett et al [4]. 
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